This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Committees Critical of Avandia
Plurality of Agency's Expert Panel Members Votes to Pull Product From Market
By News Staff
During a July 13-14 joint meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the agency's Drug Safety and Risk Management Advisory Committee, 18 of 33 committee members indicated that available data on rosiglitazone, which is a member of the thiazolidinedione class of drugs, are sufficient to raise significant safety concerns for ischemic cardiovascular events in patients with type 2 diabetes in relation to nonthiazolidinediones, such as metformin and the sulfonylureas. Six committee members disagreed.
Twenty-one of the members of the two committees, however, indicated that data are sufficient to raise significant safety concerns about ischemic cardiovascular events in patients with type 2 diabetes who take rosiglitazone compared with use of a second thiazolidinedione, pioglitazone, which is marketed as Actos.
Nine panelists said they were not able to make a finding regarding either question.
When asked what regulatory action the FDA should pursue in regard to rosiglitazone, 12 committee members recommended that the drug be removed from the market. Ten members, however, recommended allowing continued marketing of the medication on the condition that the current package label is revised to include additional warnings and additional restrictions put in place. According to the FDA, such restrictions could include limiting prescribing to physicians who have enrolled in a program and completed required training.
In addition, seven members of the committees recommended allowing continued marketing of rosiglitazone with only the addition of further label warnings, three voted for continued marketing with no label changes, and one member abstained.
Members of the two committees also were asked whether the multicenter Thiazolidinedione Intervention with Vitamin D Evaluation, or TIDE, trial should continue if rosiglitazone remains on the market. Nineteen members recommended that the trial continue in that scenario. Eleven opposed that option.
TIDE is testing the cardiovascular effects of long-term treatment with either rosiglitazone or pioglitazone when used as part of standard of care compared to a similar standard of care without use of either drug in patients with type 2 diabetes who have a history of, or are at risk for, cardiovascular disease. The trial also is evaluating the effects of long-term vitamin D supplementation on mortality and cancer.
It's worth noting that CBS News reported July 14 that all TIDE arms being conducted in India have been suspended, although the trial continues in hundreds of other sites worldwide. The NIH's ClinicalTrials.gov website confirms this action.
According to the NIH, TIDE is not expected to be completed until 2015.
Joshua Sharfstein, M.D., the FDA's principal deputy commissioner, said in a July 8 media briefing before the joint meeting of the two committees that there was no set timeline for the FDA to act on the recommendations of its expert panels.
"Obviously, we're going to have to look at a lot of information and really understand the advice that we're getting," Sharfstein said, "and we're going to try to make a decision as quickly as we can under those circumstances."
Meanwhile, GSK said in a July 15 news release that it will record a $2.36 billion legal charge in the second quarter of fiscal year 2010 for settlements related to rosiglitazone; a U.S. Department of Justice investigation into the manufacturer's Cidra, Puerto Rico, facility; and product liability and antitrust litigation related to GSK's antidepressant drug paroxetine, which is marketed as Paxil.
GSK said it would pay $750 million to settle a Department of Justice investigation of its now shuttered Puerto Rico facility, which once produced Avandia and the combination rosiglitazone/metformin drug Avandamet.
The manufacturer did not disclose the amount of the rosiglitazone settlements, but Bloomberg L.P. reported July 13 that GSK had settled about 10,000 liability cases for $460 million.
Elsewhere, the Committee for Medicinal Products for Human Use was scheduled to review the benefit/risk profile of rosiglitazone on behalf of the European Medicines Agency -- the European Union's FDA counterpart -- during a July 19-22 meeting.
Rosiglitazone also is the subject of an ongoing inquiry by the U.S. Senate Committee on Finance.
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Though Waning, H7N9 Still Poses Pandemic Potential
AUA Says No to Routine PSA Screening
AAFP Criticizes Appeal of Plan B One-Step Ruling
AAFP to Hospitals: Stop Early Elective Deliveries
AAFP, USPSTF Differ Somewhat on HIV Screening Guidance
Zoledronic Acid Confers Both Pros, Cons
ACP Issues Guidance on PSA Screening
Abbott Recalls FreeStyle InsuLinx Blood Glucose Meter
Discuss Drug Options With Women at Risk for Breast Cancer
Shingles Vaccine Effective, But Uptake Is Low
Evidence Lacking to Make Oral Cancer Screening Recommendation
Two External Guidelines Get Qualified AAFP Endorsement
USPSTF Recommends BRCA Testing for High-risk Women
Primary Care, Public Health Look for Ways to Integrate
Malfunction Prompts Glucose Meter Recall
Evidence Lacking on PAD Screening, Says USPSTF
Azithromycin Poses Arrhythmia Risk, Says FDA
Vets With PTSD Often Prescribed Inappropriate Meds
AIM-HI Offers Grants to Combat Childhood Obesity
USPSTF Says No to Low-dose Vitamin D, Calcium to Prevent Fractures
PCV13, HibMenCY Vaccine Changes Approved by ACIP
AAFP, Other Groups Release More Choosing Wisely Lists
National Office Champions Tobacco Cessation Project Successful
USPSTF Issues Draft Statement on Glaucoma Screening
Study Examines Overuse, Inappropriate Use of Health Services
Apply to Become an AAFP Vaccine Science Fellow
Study Looks to Reduce PSA Screening Risks
AAP Issues New Clinical Guidance on Type 2 Diabetes
CDC: Adult Vaccination Rates Still Too Low
Pertussis Outbreaks Declining, but Immunization Still Key
2013 Immunization Schedules Include Several Changes
FDA Warns of Liver Injury Risk With Samsca Use
FDA Approves First Recombinant Trivalent Influenza Vaccine
AAFP, USPSTF: Screen Women of Childbearing Age for Partner Violence
Breast Cancer Screening in Older Women Costly, Likely Ineffective
CDC Gives Flu Update, Urges Continued Vaccination
Aerobic Exercise Beats Resistance Training for Weight Control
